Clinical Trial Update: Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and immunogenicity of 2 or 3 doses of the GSK HRV vaccine in healthy infants in South Africa has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rotavirus Gastroenteritis
• Rotavirus Infections

Drugs mentioned

• GSK HRV Vaccine (Rotavirus vaccine, live attenuated)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Rotavirus | Phase 2 | Status: COMPLETED